Creating Healthier Communities Convenes National Leaders to Launch Bold Goal: Cut America's Life Expectancy Gap in Half Within a Decade ...
Lawmakers fuel the national debt crisis with an $11 billion farm bailout nobody needs The war in Iran is being used to justify an $11.1 billion farm bailout, but the claims don't add up. Most of the ...
Medtronic has historically held roughly 50% share in its core heart devices. It's also the market leader in spinal products, insulin pumps, and neuromodulators for chronic pain. Medtronic's Hugo robot ...
This High-Quality Stock Is on Sale; Should You Buy the Dip?
Medalist Rating covers product that tracks indices created or licensed by Morningstar. See Disclosure for more details.
Medalist Rating covers product that tracks indices created or licensed by Morningstar. See Disclosure for more details.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Will FBNDX outperform in the future? Get our overall rating based on a fundamental assessment of the pillars below.
The 30-year Treasury yield is closing in on 5.2%. A surge to 6% could slam stocks.
AbbVie's next-generation immunology drugs targeting the IL-23 (Skyrizi) and JAK (Rinvoq) pathways are mitigating biosimilar headwinds to older blockbuster Humira. AbbVie has had to depend on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results